The rationale for immunotherapy is based on the findings that specific CD8+ T cell inhibits various tumor-associated antigens (TAAs) in HCC patients and T-cell infiltration in the tumor tissue has clinical benefit. Here, CD8A is linked to hepatocellular carcinoma.